Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Last Updated: March 30, 2023

Details for Patent: 7,208,489

✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $100
Remove trial restrictions

Which drugs does patent 7,208,489 protect, and when does it expire?

Patent 7,208,489 protects IBRANCE and is included in one NDA.

This patent has seventy-three patent family members in forty-nine countries.

Summary for Patent: 7,208,489

Title:	2-(pyridin-2-ylamino)-pyrido [2,3-d]pyrimidin-7-ones
Abstract:	The present invention provides substituted 2-aminopyridines useful in treating cell proliferative disorders. The novel compounds of the present invention are potent inhibitors of cyclin-dependent kinases 4 (cdk4) ##STR00001##
Inventor(s):	Barvian; Mark (Ann Arbor, MI), Booth; Richard John (Ann Arbor, MI), Quin, III; John (Ann Arbor, MI), Repine; Joseph Thomas (Ann Arbor, MI), Sheehan; Derek J. (Dexter, MI), Toogood; Peter Laurence (Ann Arbor, MI), Vanderwel; Scott Norman (Ann Arbor, MI), Zhou; Hairong (Ann Arbor, MI)
Assignee:	Warner-Lambert Company (Morris Plains, NJ)
Application Number:	11/046,126
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,208,489
Patent Claim Types: see list of patent claims	Compound; Composition;

Drugs Protected by US Patent 7,208,489

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-001	Feb 3, 2015		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y	Y	Y		⤷ Sign Up
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-002	Feb 3, 2015		RX	Yes	No	⤷ Sign Up	⤷ Sign Up	Y	Y	Y		⤷ Sign Up
Pfizer	IBRANCE	palbociclib	CAPSULE;ORAL	207103-003	Feb 3, 2015		RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up	Y	Y	Y		⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 7,208,489

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
African Regional IP Organization (ARIPO)	1767	⤷ Sign Up
Argentina	038814	⤷ Sign Up
Argentina	083686	⤷ Sign Up
Austria	314370	⤷ Sign Up
Australia	2003237009	⤷ Sign Up
Brazil	0307057	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt

Johnson and Johnson

Harvard Business School

Express Scripts

Colorcon

Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.